Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 89 for:    NIDDK endocrine and diabetes | Recruiting, Not yet recruiting, Available Studies

Studies of Elevated Parathyroid Activity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00001277
Recruitment Status : Recruiting
First Posted : November 4, 1999
Last Update Posted : September 12, 2019
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) )

Brief Summary:

Patients whose parathyroid activity is elevated above normal are referred to as having hyperparathyroidism. This study will help researchers better understand the causes of hyperthyroidism and to evaluate and improve methods for diagnosis and treatment.

In this study, patients diagnosed with or suspected of having hyperparathyroidism will be selected to participate. In addition, patients with related conditions such as parathyroid tumors, will also be selected.

Subjects will be asked to provide blood and urine for testing to confirm their condition. They will then be surgically treated by removal of the parathyroid gland(s) (parathyroidectomy).

Subjects with parathyroid tumors will undergo several diagnostic tests to determine the exact location of the tumor as well as the tumor's activity. The tests may include; ultrasounds, nuclear scanning, CT scans, MRI, and specialized blood testing.

Sometimes parathyroidectomy leads to hypoparathyroidism. Options for treating the patients after the surgical procedure will also be addressed. Calcium and Vitamin D supplements are typically the mainstay of post parathyroidectomy therapy. Other potential treatments include transplanting the parathyroid gland(s) to other areas of the body.


Condition or disease
Hyperparathyroidism Hypocalcemia Parathyroid Neoplasm Multiple Endocrine Neoplasia MEN1

Detailed Description:
Patients with confirmed or suspected primary hyperparathyroidism or complications therefrom (such as postoperative hypoparathyroidism) will be admitted for diagnosis and treatment. The principal diagnostic components are calcium in serum and urine, parathyroid hormone in serum, and mutation tests on germline or tumor DNA. Patients with moderately to severe primary hyperparathyroidism will be treated. Treatment will be mainly by parathyroidectomy. Preoperative testing to localize parathyroid neoplasm(s) will be used usually and with more extended methods in cases with prior neck surgery. Other options are medications or no intervention. Patients with a hyperparathyroid syndrome may be managed for their extraparathyroid features (medical management or surgical treatment). Preoperative tumor localization tests will be selected according to clinical indications from the following: ultrasound, technetium-thallium scan, computerized tomography, magnetic resonance imaging, somatostatin receptor imaging, fine needle aspiration for parathyroid hormone assay, selective arteriogram, selective venous catheterization for parathyroid hormone assay. Options for management of postoperative hypocalcemia include calcium, vitamin D analogs, parathyroid autografts and synthetic parathyroid hormone. Research specimens may consist of blood or tumors. In addition, a substudy for patients with multiple endocrine neoplasia type 1 (MEN1) will assess the utility of two PET/CT scans with radiotracers (68Gallium-DOTATATE and 18F-DOPA).

Layout table for study information
Study Type : Observational
Estimated Enrollment : 2000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Studies of Hyperparathyroidism and Related Disorders
Actual Study Start Date : March 10, 1991

Resource links provided by the National Library of Medicine


Group/Cohort
1
Patients with confirmed or suspected primary hyperparathyroidism or complications therefrom (such as postoperative hypoparathyroidism) will be admitted for diagnosis and treatment.



Primary Outcome Measures :
  1. Evaluate natural history of hyperparathyroidism [ Time Frame: Yearly ]
    The purpose of this study is to understand the causes of primary hyperparathyroidism, to evaluate and improve methods for diagnosis and treatment, and to provide insight into the mechanisms of normal parathyroid function. Hereditary causes of primary hyperparathyroidism will be characterized. Methods of pre- operative parathyroid gland localization will be evaluated (6, 7, 8). Genes that contribute to development of parathyroid tumors will be analyzed (4, 9, 10).


Secondary Outcome Measures :
  1. To compare the efficacy of 68Ga-Dotatate PET/CT scan versus 18F-DOPA PET/CT, MRI and CT scan [ Time Frame: Yearly ]
    To compare the efficacy of 68Ga-Dotatate PET/CT scan versus 18F-DOPA PET/CT, MRI and CT scan in detecting known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors in yearly intervals as per standard of care.

  2. To evaluate 68Gallium-Dotatate versus 18F-DOPA PET/CT uptake in NETs and its association with tumor differentiation [ Time Frame: Yearly ]
    There is the potential for direct benefit for patients participating in this study if the study results show 18F- DOPA PET/CT imaging to be more accurate than the current standard 68Gallium- DOTATATE at detecting primary lesions or metastasis. The future application of 18F- DOPA imaging modality in other patients could lead to early detection of solid gastrointestinal or pancreatic lesions and metastatic lesions, which would improve early management of these lesions and potentially have an impact on the overall course of the disease.

  3. To determine whether 68Gallium-Dotatate and/or 18F-DOPA PET/CT uptake value is predictive of tumor growth and/or disease progression and of its differentiation state. [ Time Frame: Yearly ]
    There is the potential for direct benefit for patients participating in this study if the study results show 18F- DOPA PET/CT imaging to be more accurate than the current standard 68Gallium- DOTATATE at detecting primary lesions or metastasis. The future application of 18F- DOPA imaging modality in other patients could lead to early detection of solid gastrointestinal or pancreatic lesions and metastatic lesions, which would improve early management of these lesions and potentially have an impact on the overall course of the disease.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with confirmed or suspected primary hyperparathyroidism or complications therefrom (such as postoperative hypoparathyroidism) will be admitted for diagnosis and treatment. Patients with a hyperparathyroid syndrome may be managed for their extraparathyroid features (medical management or surgical treatment). Preoperative tumor localization tests will be selected according to clinical indications from the following: ultrasound, technetium-thallium scan, computerized tomography, magnetic resonance imaging, somatostatin receptor imaging, fine needle aspiration for parathyroid hormone assay, selective arteriogram, selective venous catheterization forparathyroid hormone assay. In addition, a substudy for patients with multiple endocrine neoplasia type 1 (MEN1) will assess the utility of two PET/CT scans with radiotracers (68Gallium-DOTATATE and 18F-DOPA).
Criteria
  • INCLUSION CRITERIA:
  • Patients who have genetically confirmed MEN1 or clinical criteria of MEN1.
  • Age greater than age 18.
  • For females: Negative urine pregnancy test OR post-menopausal for at least 2 years OR patient has had a hysterectomy

EXCLUSION CRITERIA:

  • Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure or congestive cardiac failure
  • Patients unable or unwilling to give informed consent
  • Pregnant or lactating women: Pregnant women are excluded from this study because the effects of 68Ga-DOTATATE in pregnancy are not known. Because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of 68Ga-DOTATATE in the mother, women who are breastfeeding are also excluded from this study
  • Patients that have recognized concurrent active infection
  • Patients with exposure to, or usage of, any investigational product or device, excluding 18F-DOPA scans, within 30 days prior to dosing
  • Patients with known hypersensitivity to carbidopa, or who are concurrently taking a nonselective monoamine oxidase (MAO) inhibitor..

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001277


Contacts
Layout table for location contacts
Contact: William F Simonds, M.D. (301) 496-9299 wfs@helix.nih.gov
Contact: Jenny E Blau, M.D. (301) 827-1930 jenny.blau@nih.gov

Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov   
Sponsors and Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Layout table for investigator information
Principal Investigator: Jenny E Blau, M.D. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier: NCT00001277     History of Changes
Other Study ID Numbers: 910085
91-DK-0085
First Posted: November 4, 1999    Key Record Dates
Last Update Posted: September 12, 2019
Last Verified: June 24, 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ):
Hypoglycemia
Genetics
Hyperparathyroidism
Additional relevant MeSH terms:
Layout table for MeSH terms
Endocrine Gland Neoplasms
Multiple Endocrine Neoplasia
Endocrine System Diseases
Parathyroid Neoplasms
Hypocalcemia
Hyperparathyroidism
Neoplasms
Parathyroid Diseases
Calcium Metabolism Disorders
Metabolic Diseases
Water-Electrolyte Imbalance
Neoplasms by Site
Neoplasms, Multiple Primary
Neoplastic Syndromes, Hereditary
Genetic Diseases, Inborn
Head and Neck Neoplasms